Trial reportDrug and alcohol dependence2010
Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.
Trial report in Drug and alcohol dependence, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Maintenance treatments for opiate -dependent adolescents.The Cochrane database of systematic reviews · 2014Pooled it
- Detoxification treatments for opiate dependent adolescents.The Cochrane database of systematic reviews · 2014Pooled it
- Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain.Drug and alcohol dependence · 2016Trial
- Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.Experimental and clinical psychopharmacology · 2015Trial
- Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.The American journal on addictions · 2015Trial
- Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth.Journal of the American Academy of Child and Adolescent Psychiatry · 2011Trial
- Changes in pain during buprenorphine maintenance treatment among patients with opioid use disorder and chronic pain.Journal of consulting and clinical psychology · 2022Article
- Psychological Flexibility, Pain Characteristics and Risk of Opioid Misuse in Noncancerous Chronic Pain Patients.Journal of clinical psychology in medical settings · 2021Article
- Building a Group-Based Opioid Treatment (GBOT) blueprint: a qualitative study delineating GBOT implementation.Addiction science & clinical practice · 2019Article
- Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose.Pain medicine (Malden, Mass.) · 2019Article
- Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.Addiction (Abingdon, England) · 2017Article
- Pain in the management of opioid use disorder.Journal of pain research · 2016Article
- Impact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysis.Substance abuse : research and treatment · 2015Review
- Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.Drug and alcohol dependence · 2014Review
- "This is not who I want to be:" experiences of opioid-dependent youth before, and during, combined buprenorphine and behavioral treatment.Substance use & misuse · 2014Article
- Morphine-induced mu opioid receptor trafficking enhances reward yet prevents compulsive drug use.EMBO molecular medicine · 2011Article
- Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review.Journal of addiction medicineReview
- Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study.The American journal on addictionsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
introductionThe present investigation examines baseline patient characteristics to predict dosing of buprenorphine-naloxone, a promising treatment for opioid addiction in youths.
methodsThis study of 69 opioid-dependent youths is a secondary analysis of data collected during a National Institute on Drug Abuse (NIDA) Clinical Trials Network study. Outpatients aged 15-21 were randomized to a 12-week buprenorphine-naloxone dosing condition (including 4 weeks of taper). Predictors of dosing included sociodemographic characteristics (gender, race, age, and education), substance use (alcohol, cannabis, cocaine, and nicotine use), and clinical characteristics (pain and withdrawal severity).
resultsMost (75.4%) reported having either "some" (n=40, 58.0%) or "extreme" (n=12, 17.4%) pain on enrollment. Maximum daily dose of buprenorphine-naloxone (19.7 mg) received by patients reporting "extreme" pain at baseline was significantly higher than the dose received by patients reporting "some" pain (15.0mg) and those without pain (12.8 mg). In the adjusted analysis, only severity of pain and withdrawal significantly predicted dose. During the dosing period, there were no significant differences in opioid use, as measured by urinalysis, by level of pain.
conclusionThese data suggest that the presence of pain predicts buprenorphine-naloxone dose levels in opioid-dependent youth, and that patients with pain have comparable opioid use outcomes to those without pain, but require higher buprenorphine-naloxone doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.